Argent Biopharma Limited has released a press release.
Internal Costs Review Completed and Board Change
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- $800,000 of funding received through Mercer Facility
- Completion of CimetrA Efficacy Pre-clinical Trial
- US$1,000,000 ArtemiC order delivered to US partner, AMC
- Publication of Peer Reviewed Glioblastoma Research
- Long COVID study Results
Later from Argent Biopharma
- Results of CimetrA bioanalytics pre-clinal trial
- Refinancing and Extension to Convertible Security Agreements
- Provision of US$600,000 Funding and change of CFO
- Completion of CimetrA Mechanism of Action study
- ArtemiC Listed as OTC Drug in USA, AMC Places US$2m Order
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma